Motexafin gadolinium: A redox-active tumor selective agent for the treatment of cancer

Current Opinion in Oncology

Volumn 16, Issue 6, 2004, Pages 576-580

  Evens, Andrew M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Apoptosis; Cancer; Motexafin gadolinium; Reactive oxygen species; Redox

Indexed keywords

ASCORBIC ACID; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GADOLINIUM TEXAPHYRIN; GLUTATHIONE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PORPHYRIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; RITUXIMAB; TEMOZOLOMIDE; THIOREDOXIN; THIOREDOXIN REDUCTASE;

APOPTOSIS; ASTHENIA; BRAIN METASTASIS; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG SAFETY; DRUG SELECTIVITY; GLIOBLASTOMA; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERTENSION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM PERMISSIBLE DOSE; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATION REDUCTION REACTION; PARESTHESIA; PRIORITY JOURNAL; PSEUDOPORPHYRIA; RASH; REVIEW; SCLERA DISEASE; SIDE EFFECT; SKIN DISCOLORATION; VOMITING;

EID: 8344244538     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000142073.29850.98     Document Type: Review

References (37)

1. Sessler JL, Miller RA: Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 2000, 59:733-739.
2. Magda D, Gerasimchuk N, Lecane P, et al.: Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem Commun (Camb) 2002:2730-2731.
3. Xu S, Zakian K, Thaler H, et al.: Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 2001, 49:1381-1390.
4. Magda D, Lepp C, Gerasimchuk N, et al.: Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 2001, 51:1025-1036.
5. Toyokuni S: Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999, 49:91-102.
6. Cerutti PA: Prooxidant states and tumor promotion. Science 1985, 227:375-381.
7. Jing Y, Dai J, Chalmers-Redman RM, et al.: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999, 94:2102-2111.
8. Gromer S, Urig S, Becker K: The thioredoxin system-from science to clinic. Med Res Rev 2004, 24:40-89.
9. Gartenhaus RB, Prachand SN, Paniaqua M, et al.: Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 2002, 8:566-572.
10. Grad JM, Bahlis NJ, Reis I, et al.: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001, 98:805-813.
11. Ochi T, Nakajima F, Sakurai T, et al.: Dimethylarsinic acid causes apoptosis in HL-60 cells via interaction with glutathione. Arch Toxicol 1996, 70:815-821.
12. Bellosillo B, Villamor N, Lopez-Guillermo A, et al.: Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001, 98:2771-2777.
13. Armstrong JS, Steinauer KK, Hornung B, et al.: Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ 2002, 9:252-263.
14. Wllliamson JM, Boettcher B, Meister A: Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis. Proc Natl Acad Sci U S A 1982, 79:6246-6249.
15. Meister A: Glutathione metabolism and its selective modification. J Biol Chem 1988, 263:17205-17208.
16. Sun J, Chen Y, Li M, et al.: Role of antioxidant enzymes on ionizing radiation resistance. Free Radic Biol Med 1998, 24:586-593.
17. Powis G, Montfort WR: Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 2001, 41:261-295.
18. Dalton WS. Targeting the mitochondria: an exciting new approach to myeloma therapy [see commentary]. Clin Cancer Res 2002, 8:3643-3645, 3658-3668.
19. Brookes PS, Levonen AL, Shiva S, et al.: Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen species. Free Radic Biol Med 2002, 33:755-764.
20. Evens AM, Prachand S, Shi B, et al.: Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. Clin Cancer Res 2004, 10:1481-1491.
21. Dvorakova K, Waltmire CN, Payne CM, et al.: Induction of mitochondrial changes in myeloma cells by imexon. Blood 2001, 97:3544-3551.
22. Byrd JC, Kitada S, Flinn IW, et al.: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002, 99:1038-1043.
23. Chen Q, Chai YC, Mazumder S, et al.: The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death Differ 2003, 10:323-334.
24. Li PF, Dietz R, von Harsdorf R: p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J 1999, 18:6027-6036.
25. Woodburn KW: Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J Pharmacol Exp Ther 2001, 297:888-894.
26. Miller RA, Woodburn K, Fan Q, et al.: In vivo animal studies with gadolinium (III) texaphyrins as a radiation enhancer. Int J Radiat Oncol Biol Phys 1999, 45:981-989.
27. Young SW, Qing F, Harriman A, et al.: Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci U S A 1996, 93:6610-6615.
28. Donnelly ET, Liu Y, Fatunmbi YO, et al.: Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. Int J Radiat Oncol Biol Phys 2004, 58:1570-1576.
29. Miller RA, Woodburn KW, Fan Q, et al.: Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res 2001, 7:3215-3221.
30. Miller RFQ, Lee I, Magda D: Motexafin gadolinium (Gd) increases tumor response to chemotherapy in Lewis lung cancer (LLC) animal model. ASCO Proc 2002, 21:117a.
31. Young SW, Sidhu MK, Qing F, et al.: Preclinical evaluation of gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging. Invest Radiol 1994, 29:330-338.
32. Rosenthal DI, Nurenberg P, Becerra CR, et al.: A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999, 5:739-745.
33. Viala J, Vanel D, Meingan P, et al.: Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology 1999, 212:755-759.
34. Carde P, Timmerman R, Mehta MP, et al.: Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001, 19:2074-2083.
35. Mehta MP, Shapiro WR, Glantz MJ, et al.: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 2002, 20:3445-3453.
36. Mehta MP, Rodrigus P, Terhaard CH, et al.: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003, 21:2529-2536. This is an early clinical report on the clinical outcomes of patients treated with combination MGd and WBRT.
37. Meyers CA, Smith JA, Bezjak A, et al.: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004, 22:157-165. Through a multicenter phase III randomized trial, combination MGd and WBRT improved memory and executive ,function and significantly prolonged time to neurologic progression in patients with brain metastases from lung cancer. The authors also established sensitive neurocognitive tests as a reliable measure of brain function. Moreover, they showed that a combination of tumor prognostic variables and brain function assessments predicted survival better than tumor variables alone.